Tag Archives: PARP inhibitor

November, 2018

October, 2018

June, 2018

May, 2018

January, 2018

December, 2017

October, 2017

June, 2017

  • 19 June

    Clovis Oncology’s Ovarian Cancer Drug Succeeds in Late-Stage Study

    BOULDER, Colo.–(BUSINESS WIRE)–Clovis Oncology, Inc. (NASDAQ: CLVS) today announced topline data from the confirmatory phase 3 ARIEL3 trial of rucaparib, which successfully achieved the primary endpoint of improved progression-free survival (PFS) by investigator review in each of the three populations studied. PFS was also improved in the rucaparib group compared …